drugset / Trial / NCT05588557

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers

NCT05588557

Phase 1 Completed 24 enrolled Nang Kuang Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study focuses on ND-340 extended release injection suspension for healthy volunteers with a one-time nerve blockade to determine the safety, tolerability, and pharmacokinetic profile.

Timeline

Start
2022-07-08
Primary completion
2024-03-19
Completion
2024-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 150 mg Other
Subject Bupivacaine Other / unclassified Other

Indications